Literature DB >> 15161571

Screening for prostate cancer: updated experience from the Tyrol study.

Wolfgang Horninger1, Andreas Berger, Alexandre Pelzer, Helmut Klocker, Wilhelm Oberaigner, Dieter Schönitzer, Gianluca Severi, Chris Robertson, Peter Boyle, Georg Bartsch.   

Abstract

The aim of the Tyrol study was to monitor the impact of screening in a natural experiment by comparing prostate cancer mortality in Tyrol, where prostate-specific antigen (PSA) testing was introduced at no charge, with the rest of Austria, where it was not strictly organized and not free of charge. In 1993, PSA testing was made freely available to men between the ages of 45 and 75 years in the Federal State of Tyrol, Austria. At least 70% of all of the men in this age range have been tested at least once during the first 10 years of the study. Initially, only total PSA was measured, but free PSA measurement was added in 1995. Since 2001, complexed PSA also has been measured. Digital rectal examination was not part of the screening examination. Significant migration to lower clinical and pathological stages has been observed since the introduction of this screening program. These findings are consistent with the hypothesis that the policy of making PSA testing freely available, and the wide acceptance by men in the population, is associated with a reduction in prostate cancer mortality in an area in which urology services and radiotherapy are available freely to all patients. It is our opinion that most of this decline is likely a result of aggressive downstaging and successful treatment and that any contribution from detecting and treating early cancers will become apparent in the years to come.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161571     DOI: 10.1007/s11934-004-0040-8

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  26 in total

1.  Prostate specific antigen (PSA) testing as screening for prostate cancer: the current controversy.

Authors:  P Boyle
Journal:  Ann Oncol       Date:  1998-12       Impact factor: 32.976

2.  PSA-based screening for prostate cancer in asymptomatic younger males: pilot study in blood donors.

Authors:  A Reissigl; J Pointner; W Horninger; H Strasser; P Mayersbach; H Klocker; D Schönitzer; G Bartsch
Journal:  Prostate       Date:  1997-01-01       Impact factor: 4.104

3.  Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes.

Authors:  E Lăără; N E Day; M Hakama
Journal:  Lancet       Date:  1987-05-30       Impact factor: 79.321

4.  Frequency and clinical significance of transition zone cancer in prostate cancer screening.

Authors:  A Reissigl; J Pointner; H Strasser; O Ennemoser; H Klocker; G Bartsch
Journal:  Prostate       Date:  1997-02-01       Impact factor: 4.104

Review 5.  Epidemiology of prostate cancer chemoprevention.

Authors:  P Boyle; G Severi
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

6.  Reduction in breast cancer mortality due to the introduction of mass screening in The Netherlands: comparison with the United Kingdom.

Authors:  E van den Akker-van Marle; H de Koning; R Boer; P van der Maas
Journal:  J Med Screen       Date:  1999       Impact factor: 2.136

7.  Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

Authors:  B F Hankey; E J Feuer; L X Clegg; R B Hayes; J M Legler; P C Prorok; L A Ries; R M Merrill; R S Kaplan
Journal:  J Natl Cancer Inst       Date:  1999-06-16       Impact factor: 13.506

8.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

Authors:  J E Oesterling; S J Jacobsen; C G Chute; H A Guess; C J Girman; L A Panser; M M Lieber
Journal:  JAMA       Date:  1993-08-18       Impact factor: 56.272

9.  The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project.

Authors:  C Mettlin; G P Murphy; R J Babaian; A Chesley; R A Kane; P J Littrup; F K Mostofi; P S Ray; A M Shanberg; A Toi
Journal:  Cancer       Date:  1996-01-01       Impact factor: 6.860

10.  The pathological features and prognosis of prostate cancer detectable with current diagnostic tests.

Authors:  M Ohori; T M Wheeler; J K Dunn; T A Stamey; P T Scardino
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.